Related Experiment Video

Updated: Apr 18, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.4K

Selective Janus associated kinase 1 inhibition as a therapeutic target in myelofibrosis

John Mascarenhas1

  • 1a Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai , New York , NY , USA.

Leukemia & Lymphoma
|January 15, 2015
PubMed

Insights

Selective JAK1 inhibition may treat myelofibrosis (MF) symptoms without myelosuppression. This approach offers potential combination therapies and further clarifies JAK1

Area of Science:

  • Oncology
  • Hematology
  • Molecular Biology

Background:

  • Hyperactive Janus associated kinase-signal transducers and activators of transcription (JAK-STAT) signaling drives myelofibrosis (MF) pathogenesis.
  • Approved JAK1/2 inhibitor ruxolitinib shows clinical success but has limitations including myelosuppression.
  • JAK1 inhibition may reduce MF symptoms without impacting bone marrow function.

Purpose of the Study:

  • To evaluate the therapeutic potential of selective JAK1 inhibition in myelofibrosis.
  • To explore JAK1 inhibition as a strategy to mitigate MF-related symptoms and myelosuppression.
  • To assess JAK1 inhibitors as combination therapy candidates for MF treatment.

Main Methods:

  • Investigating the role of JAK1 signaling in MF pathogenesis.
  • Evaluating the effects of selective JAK1 inhibition on MF symptoms and bone marrow parameters.
  • Assessing the potential of JAK1 inhibitors in combination therapies.

Main Results:

  • JAK1 inhibition can decrease inflammatory cytokine expression linked to MF symptoms.
  • Selective JAK1 inhibition may alleviate MF symptoms without causing dose-limiting thrombocytopenia or anemia.
  • Targeting JAK1 presents an opportunity to avoid myelosuppression associated with broad JAK inhibition.

Conclusions:

  • Selective JAK1 inhibition is a promising strategy for managing myelofibrosis symptoms.
  • This approach may overcome limitations of current therapies, such as myelosuppression.
  • Further research into selective JAK1 inhibition is crucial for understanding its role in MF treatment and combination strategies.
Keywords:
JAKMyelofibrosiscytokinesinhibitorrationale

More Related Videos

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-308:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.7K
Time-resolved Förster Resonance Energy Transfer Assays for Measurement of Endogenous Phosphorylated STAT Proteins in Human Cells07:12

Time-resolved Förster Resonance Energy Transfer Assays for Measurement of Endogenous Phosphorylated STAT Proteins in Human Cells

Published on: September 9, 2021

4.4K

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
14.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.3K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
11.1K